Insomnia : $4.24 Billion Industry In US.

What are the Global Growth Factors?

Growth in Global US Insomnia Market is launch of new drugs for the treatment of insomnia and government support to control rising insomnia cost. However, due to the erosion in branded drugs sales and growing adoption of generics attributed to their low cost and equal efficacy as compared to branded products may hinder the growth of the market.

What The Experts Says about the Market Growth?

The US Insomnia Market is projected to reach $4.24 Billion by 2021 from USD 3.38 Billion in 2016, at a CAGR of 4.6% during the forecast period.

Browse and in-depth TOC on "US Insomnia Market"

16 – Tables

33 - Figures

144 - Pages

Based on type of treatment, the U.S. insomnia market is categorized into pharmacological treatments and non-pharmacological treatments. The pharmacological treatments segment is further categorized into prescription sleep aids and over-the-counter sleep aids. The over-the-counter sleep aids segment is estimated to grow at the highest CAGR during the forecast period due to easier availability and low price as compared to prescription sleep aids. Moreover, according to consumer reports, a patient can save up to USD 47 a week using OTC sleep aids.

Based on non-pharmacological treatment, the market is categorized into cognitive behavioural therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies. CBTI is highly recommended therapy for insomnia patients due as its can be used with multiple approaches that enables physicians to understand and cure patients comprehensibly. The other alternative therapies include exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.

Download FREE Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55727597

The non-pharmacological treatment market is categorised into cognitive behavioural therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies. The other alternative therapies include exercise/ yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy. Most of these therapies are given in combination with CBTI and hypnotherapies in order to provide better results for insomnia patients. CBTI is the highly recommended treatment option for insomnia patients due to its most effective use with multiple approaches such as relaxation training, cognitive therapy, stimulus control (SC), sleep restriction therapy (SRT), sleep hygiene, biofeedback, and others that help doctors to understand and cure patient comprehensively. CBTI is followed by hypnotherapy, due to its advantage of curing insomnia with its root cause.

Key Market Players:

Some of the major players in the U.S. insomnia market market include Eisai Co., Ltd. (Japan), Meda Consumer Healthcare Inc. (U.S.), Merck & Co., Inc. (U.S.), Pernix Therapeutics Holdings (U.S.), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Takeda Pharmaceutical Company Ltd. (Japan), and Vanda Pharmaceuticals, Inc (U.S.).

Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=55727597

The over-the-counter sleep aids segment of U.S. insomnia pharmacological treatment market is expected to grow at the highest CAGR during the forecast period. Reasons attributing to the growth of this market includes easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid. The OTC sleep aids market is categorised into antihistamines, melatonin, valerian roots, and other herbal & dietary supplements. Other herbal & dietary supplements include sleep aids such as L-theanine, amino acids supplements, and a variety of botanicals. Growing awareness about the advantages of melatonin and valerian roots such as least amount of side effects, reduces stress levels, and its growing consumption is driving the growth of this segment in the U.S.

U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021

Professional Healthcare Consultant with more than 6 years of consulting experience